Welcome to the
Medical Science Liaison Society!
We are a 501(c)(3) Non-Profit Organization exclusively
dedicated to advancing the global MSL career!

Read more...


FREE MSL Talent Scout Service

MSL REPORTS

PRESENTATIONS

The MSL Society and the Growth of the MSL Role
Samuel Dyer, Chairman of the Board of the MSL Society
The MSL Society Conference 2013, Paris

MSL Society – Future Projects and How You Can Get Involved
Samuel Dyer, Chairman of the Board of the MSL Society
The MSL Society Conference 2013, Paris

The MSL Function in Asia
Maria Aileen N. Mabunay MD, Regional Scientific Operations Manager, Mundipharma
The MSL Society Conference 2013, Paris

3C Method For Building 'Us'
Ayse ÖLMEZ MD, Group Medical Manager, Bayer Healthcare
The MSL Society Conference 2013, Paris

MSL Training: Behind The Curtain
Belinda Gist, PhD, Director, MSL Training, Genzyme Corporation
The MSL Society Conference 2013, Paris

New MSL Team Launching
Elena Chukhraeva, MD, PhD, MSL Manager, Janssen Pharmaceuticals
The MSL Society Conference 2013, Paris

The Evolving Role of the Medical Science Liaison
Elly Grimaldi, Principal, GRS, LLC
Yavuz S. Silay, MD, MBA CEO, LabioPharma LLC
The MSL Society Conference 2013, Paris

Developing a MSL Team Structure in a Therapeutic Area and What is the Future Impact
Jennifer Williams MBA, PhD, Director of Medical Science Liaisons, Bard Medical
The MSL Society Conference 2013, Paris

Measure What Matters: A New Slant on Metrics
Kevin Appareti, MBA, Global Director, Medical Science Liaison, Philips Healthcare
The MSL Society Conference 2013, Philadelphia

Medical Liaisons: Driving Efficiencies in Product Development
Stewart H Rosen, MD, Vice President of Medical Affairs, Health Management Solutions, Quintiles
The MSL Society Conference 2013, Philadelphia

The Physician Payment Sunshine Act and MSLs: What do MSLs Believe are the Implications for Industry?
Anna Deng, PharmD, Rutgers Institute for Pharmaceutical Industry Fellowships, Bristol-Myers Squibb Justin Balint, PharmD, Rutgers Institute for Pharmaceutical Industry Fellowships, Bristol-Myers Squibb
The MSL Society Conference 2013, Philadelphia

Developing a KOL Management Program in a Medical Device Company
Kevin Appareti, Global Director, Medical Science Liaison, Philips Healthcare
eyeforpharma – Berlin 2011 KOL & Stakeholder Engagement Europe

Understand what are the opportunities to develop impacting partnerships throughout the health value chain
Hervé Drevot, VP, Cross Worlds HealthCare Professionals
eyeforpharma – Berlin 2011 KOL & Stakeholder Engagement Europe

Expert Insights into effective engagement with non-clinical opinion leaders
Dale Kummerle, Director, Virology Medical Education, Bristol - Myers Squibb
eyeforpharma – Berlin 2011 KOL & Stakeholder Engagement Europe

The lifecycle management of KOLs - from phase 1 to the end of exclusivity
Rav Seeruthun, Head of Clinical Affairs, Napp Pharmaceuticals
eyeForPharma – Berlin 2011 KOL & Stakeholder Engagement Europe

European KOL compensation: Principles for success
Samuel Dyer, Founder and CEO of MSL WORLD
eyeforpharma – Berlin 2011 KOL & Stakeholder Engagement Europe

Medical Devices: Insights for a successful engagement with surgical KOLs
Simon Freedman, VP Torax Medical.
eyeforpharma – Berlin 2011 KOL & Stakeholder Engagement Europe

The latest approaches to strategically engage and interact with external experts
Emma D'Arcy, Senior Consultant, Complete Digital
eyeforpharma – Berlin 2011 KOL & Stakeholder Engagement Europe

KOLs and the "most radical changes to the English healthcare system since the inception of the NHS" - A GP Consortium Pathfinder perspective case study
Julian Given, Head of Informatics, Newcastle Bridges GP Consortia
eyeforpharma – Berlin 2011 KOL & Stakeholder Engagement Europe

How to utilize the MSL role to create new strategic alliances
Colleen Lockitt, former MSL at fujisawa/astellas and Genzyme
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Follow regulations to work compliantly to your advantage
Andy Powrie-Smith
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Follow regulations to work compliantly to your advantage
Heather Simmonds, Director, PMCPA; Andrew Powrie-Smith, Director, ABPI; Alexander Natz, Director General, Eucope
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Development of relationships between academia and pharma. View of a pediatric hematologist and oncologist
Dirk Reinhardt
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Develop a robust contact management programme
Dirk Roosen, Hospital Account Manager, Bayer
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Case study: How Pfizer matches strategy to the changing needs of a KOL
Dirk Vander Mijnsbrugge, Senior Director Medical Affairs, Pfizer
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

ABPI Code of Practice
Heather Simmonds?Director?Prescription Medicines Code of Practice Authority
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Address compliance challenges when interacting with your KOLs
Julian Jenkins, Head of Global Medical Affairs, Ferring
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Measure your effectiveness: Criteria for measuring your Return on Engagement (ROE)
Kevin Appareti, Global Director, Medical Science Liaison, Office of Medical and Health Affairs, Philips Healthcare
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

The Bribery Act 2010: the most effective way to build credibility with your KOL interactions
Shaul Brazil, Barrister, BCL Burton Copeland solicitors
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Key elements of a successful Stakeholder Relations Program - a 4 step approach
Linda Harris, VP Stakeholder Relations & Thought Leader Strategies, Fishawack; Jo Jarvis, Director of Stakeholder Strategy, Fishawack Communications
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Can social media really increase your company profits? Pros & cons on the use of this technology
Erwin P. Meijer, PhD
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

'Who else is out there?' The broader perspective of global stakeholder engagement planning
Jo Jarvis Director of Stakeholder Strategy, Fishawack Communications
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Effective ways to connect with patient groups
Keith Allan, Head of Global Advocacy, Novartis; Susanna Palkonen, Executive Officer, European Federation of Allergy and Airways Diseases Patients' Associations (EFA)
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Develop crucial relationships with your KOLs of tomorrow
Lusine Movsesyan, International Marketing Advisor, ALK-Abello
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

MSL perspective: Engage with the right KOLs to achieve a winning result for your product
Micheal Uecker, Senior Manager MSLs, ALK-Abello
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

Engage with the right KOLs to achieve a winning result for your product: a Medical Device Insight
Simon Freedman, VP, Torax Medical
eyeforpharma – Berlin 2012 KOL & Stakeholder Engagement Europe

PODCASTS

The importance of pan-European opinion leader networks in building effective brand strategies within specialty markets
Julie Willingham, European Specialty Asset Team Leader - Vaccines Special Projects, Pfizer
Dr. Sebastian Weiß, Head of Consulting, Mederi

Developing a KOL Management Program in a Medical Device Company
Eric Silfen, SVP & Chief Medical Officer , Philips Healthcare
Kevin Appareti, Global Director, Medical Science Liaison, Philips Healthcare

Regulatory Insights: How to engage in a strict regulatory environment.
Neil Kendle, Director, Kendle Healthcare

Understand what are the opportunities to develop impacting partnerships throughout the health value chain
Hervé Drevot, VP, Cross Worlds HealthCare Professionals

Expert Insights into effective engagement with non-clinical opinion leaders
Dale Kummerle, Director, Virology Medical Education, Bristol - Myers Squibb

The lifecycle management of KOLs - from phase 1 to the end of exclusivity
Rav Seeruthun, Head of Clinical Affairs, Napp Pharmaceuticals

Manage a company - wide KOL strategy: Effective KOL management and tracking tools.
Alessandra Ingrosso, International Medical Education, Senior Manager, Vifor Pharma

New stakeholders: the key to market access
Andras Fehervary, Head Market Access & External Affairs, Novartis Oncology Europe

PANEL - Improve internal communication and coordination to unleash your company's potential
Moderator: Neil Kendle, Director, Kendle Healthcare
Dr Ernst Schilli, Consultant, Bayer Schering
Sonny Johl, Expert Strategy Manager Oncology, GSK

Panel - Understand KOLs goals and agenda to ensure a symbiotic and transparent partnership.
Moderator: Matt Evans, Director, HealthUnlocked
Dr Rob Hicks - GP
Dr Peter Ilves - GP
Michael Rutgers, Director, Dutch Asthma Foundation

Medical Devices: Insights for a successful engagement with surgical KOLs
Simon Freedman, VP Torax Medical.

The latest approaches to strategically engage and interact with external experts
Emma D'Arcy, Senior Consultant, Complete Digital

KOLs and the "most radical changes to the English healthcare system since the inception of the NHS" - A GP Consortium Pathfinder perspective case study
Julian Given, Head of Informatics, Newcastle Bridges GP Consortia

WHITEPAPERS

WEBINARS

Overcoming Challenges and Maximizing Success of KOL Engagements
Thursday, March 3rd, 2016


Optimizing MSL On-Boarding & Field Based Training
Tuesday, November 17th, 2015


MSL KPI Disconnect & MSL Job Satisfaction
Tuesday, September 8th, 2015


Optimizing MSL Impact on KOL Relationships
Thursday March 5th, 2015


Maximizing MSL Performance and KOL Engagement
Sunday, May 28th, 2015


The new MSL/KOL engagement paradigm
Wednesday October 10th, 2014 2pm London (BST), 3pm Paris (CET), 9am New York (EST)


Learn More

What is an MSL?
Our Team
Testimonials
In the Media
Benefits

Contact Us

+1 561-922-9200

admin@themsls.org

Latest Tweets

Connect With Us

Facebook Facebook Twitter Twitter
LinkedIn LinkedIn YouTube YouTube
Flickr Flickr RSS Events RSS


Copyright @ 2012 MSL Society™     All rights Reserved.